Draft:Andrew Allen
Physician scientist and biotech entrepreneur
From Wikipedia, the free encyclopedia
Andrew Allen, M.D., Ph.D. is a physician-scientist and biotechnology entrepreneur who has played a role in the development of multiple oncology therapeutics.
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 4,131 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Early life and education
Allen trained in medicine at the University of Oxford and earned a Ph.D. in immunology from Imperial College London.[1][2]
Career
Allen began his biotechnology career in oncology drug development roles at Abbott Laboratories and Chiron Corporation. In 2006 he joined Pharmion Corporation as Chief Medical Officer, where he helped lead the clinical development of Azacitidine, a DNA methylation inhibitor used for the treatment of myelodysplastic syndromes.[3]
In 2009, Allen co-founded Clovis Oncology, where he served as Chief Medical Officer until 2015. During his tenure, the company developed Rucaparib, a PARP inhibitor later approved for ovarian and prostate cancers.[4][5]
In 2015, Allen co-founded Gritstone bio and served as Chief Executive Officer, which developed neoantigen vaccines.[1]
Allen has also served on the boards of multiple biotechnology companies.[1]
Scientific contributions
Allen has contributed to the development of targeted therapies and personalized immunotherapy approaches in oncology. Allen's scientific contributions include advancing the translational science of neoantigen vaccines. In 2024, he co-authored a study in Nature Medicine analyzing samples from a Gritstone-led clinical trial, which revealed an unexpected hierarchy of neoantigen immunodominance in which T-cell responses preferentially focused on TP53-derived epitopes at the expense of clinically relevant KRAS neoantigens.[6] The study demonstrated how dominant epitopes within a multi-epitope construct can suppress immune responses to other encoded targets, helping establish broader principles of antigen competition in therapeutic cancer vaccines.